PT  - JOURNAL ARTICLE
AU  - Xu, Jiayi
AU  - Guertin, Kristin A.
AU  - Gaddis, Nathan C.
AU  - Agler, Anne H.
AU  - Parker, Robert S.
AU  - Feldman, Jared M.
AU  - Kristal, Alan R.
AU  - Arnold, Kathryn B.
AU  - Goodman, Phyllis J.
AU  - Tangen, Catherine M.
AU  - Hancock, Dana B.
AU  - Cassano, Patricia A.
TI  - Change in Plasma Alpha-Tocopherol Associations with Attenuated Pulmonary Function Decline and with <em>CYP4F2</em> Missense Variation
AID  - 10.1101/2021.07.22.21260985
DP  - 2021 Jan 01
TA  - medRxiv
PG  - 2021.07.22.21260985
4099  - http://medrxiv.org/content/early/2021/07/23/2021.07.22.21260985.short
4100  - http://medrxiv.org/content/early/2021/07/23/2021.07.22.21260985.full
AB  - Background Given its antioxidant activity, vitamin E is hypothesized to attenuate the age-related decline in pulmonary function.Objective We investigated the association between change in plasma vitamin E (ΔvitE) and pulmonary function decline and examined genetic and non-genetic factors associated with ΔvitE.Design We studied 1,144 men randomized to vitE in the Selenium and Vitamin E Cancer Prevention Trial. ΔvitE was calculated as the difference between baseline and year 3 vitE concentrations measured with gas chromatography-mass spectrometry. Pulmonary function (forced expiratory volume in the first second [FEV1]) was measured longitudinally with spirometry. We genotyped 555 participants (vitE-only arm) using the Illumina MEGAex array. We examined the association of ΔvitE with annual change in FEV1 using mixed-effects linear regression. We also examined the association of previously reported genetic and non-genetic factors with ΔvitE.Results Greater ΔvitE was associated with attenuated FEV1 decline, with stronger effects in adherent supplement responders: a 1 SD higher ΔvitE (+4 µmol/mmol free-cholesterol-adjusted α-tocopherol) attenuated FEV1 decline by ∼8.9 mL/year (P=0.014). This effect size is ∼1/4 of the effect of one year of aging, but in the opposite direction. The ΔvitE-FEV1 association was positive in never and current smokers (9.7 and 11.0 mL/year attenuated FEV1 decline, respectively), but there was little to no association in former smokers. Greater ΔvitE was associated with lower baseline α-tocopherol, higher baseline γ-tocopherol, higher baseline free cholesterol, European ancestry (vs. African ancestry) (all P<0.0001), and the minor allele of a missense variant in CYP4F2 (rs2108622-T) (2.4 µmol/L greater ΔvitE; P=0.0032).Conclusions Greater response to vitE supplementation was associated with attenuated FEV1 decline, and this response was differed by rs2108622 such that individuals with the C allele may need a higher vitE intake dose to reach the same plasma level, compared to the T allele.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialNCT00006392 (SELECT), NCT00063453 (RAS).Funding StatementThis research was supported by the National Heart, Lung, and Blood Institute (NHLBI) grants R01 HL071022 and R21 HL125574, and the National Cancer Institute/Division of Cancer Prevention grants U10 CA37429 and 5UM1CA182883. Genotyping services were provided through the RS&G Service by the Northwest Genomics Center at the University of Washington, Department of Genome Sciences, under U.S. Federal Government contract number HHSN268201100037C from the NHLBI. This research was also supported, in part, by the Cornell University Center for Vertebrate Genomics Scholarship Award (to J Xu), and the American Society for Nutrition Pfizer Predoctoral Fellowship (to J Xu). The study sponsors were not involved in study design, data collection, data analysis, data interpretation, report writing or decisions to submit the paper for publication. JX and PAC had final responsibility for the decision to submit for publication.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The Cornell University IRB and the IRB at each of the 16 study sites approved the study.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData described in the manuscript, code book, and analytic code will be made available upon request.